Fig. 6: SAR131675 decreases high-glucose and palmitate-induced vascular endothelial cell growth factor-C (VEGF-C), vascular endothelial cell growth factor receptor-3 (VEGFR-3), and LYVE-1 expression in human kidney-2 (HK2) cells. | Cell Death & Disease

Fig. 6: SAR131675 decreases high-glucose and palmitate-induced vascular endothelial cell growth factor-C (VEGF-C), vascular endothelial cell growth factor receptor-3 (VEGFR-3), and LYVE-1 expression in human kidney-2 (HK2) cells.

From: Inhibition of lymphatic proliferation by the selective VEGFR-3 inhibitor SAR131675 ameliorates diabetic nephropathy in db/db mice

Fig. 6

To determine whether the addition of SAR131675 might modulate lymphangiogenesis in human proximal tubular epithelial HK2 cells, the cells were stimulated with palmitate (500 μM) and exposed to SAR131675 at 1, 10, or 100 nM in low-glucose (LG; 5 mmol/L d-glucose) or high-glucose (HG; 30 mmol/L d-glucose) medium. Representative western blots for VEGF-C, VEGFR-1, VEGFR-2, VEGFR-3, and β-actin and quantitative data. *P < 0.05, **P < 0.01 vs. LG control

Back to article page